Innate Immune Modulators

For The Prevention of Complications Associated with Respiratory Viral Infections

Ena Respiratory

About Us

ENA Respiratory Pty Ltd is a clinical-stage pharmaceutical company developing innate immune modulators, delivered as a convenient nasal spray for the prevention of complications associated with respiratory viral infections in at-risk populations.

At-Risk Populations Due to Comorbid Conditions

  • COPD, Asthma
  • Congestive Heart Failure
  • Chronic Kidney Disease
  • Lymphoma/Chronic Leukemia
  • High-Dose Corticosteroids
  • Elderly (>65 years old)

At Risk Occupations

  • Healthcare workers
  • Teachers
  • Transportation workers
  • Military Personnel

 

 

Our most advanced drug, INNA-051 is in clinical development. Add a link to the INNA-051 product page.

Our Investors

Headquartered in Melbourne Australia, the company has secured a Series A investment.

Brandon Capital

Brandon Capital

Find out more
Minderoo Foundation

Minderoo Foundation

Find out more
Uniseed

Uniseed

Find out more

 Our Partnerships

BLUE KNIGHT

BLUE KNIGHT

In 2022, ENA Respiratory was selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and U.S. BARDA.

Find out more
COPD FOUNDATION

COPD FOUNDATION

In 2022, ENA Respiratory partnered with the US-based COPD Foundation to accelerate the clinical development of INNA-051 in COPD through its access to patients, a global network of accredited centres, scientific expertise, and patient investigators.

Find out more
U.S. Department of Defense

U.S. Department of Defense

In 2023, ENA Respiratory was awarded a USD4.38 million contract from the U.S. Department of Defense to support the ongoing development of INNA-051.

Find out more